Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I take it as a good sign. How rare is it for a BB listed stock not to trade for days as MMs are always overwhelmed by the need to make a market and feel compelled to fill orders by taking the price down? Don't see that here. Just waiting for the Q report due out soon (or later).
no trades for days and same pps for weeks..
only a few hundred dollars worth traded so far this month...
HELLO... Hello... hello...
Very quiet here. Seems to be an echo. Even the SP repeats daily.
If you mean by short term in the next 6 weeks, I think that with back to back profitable quarters $2 is completely doable by end of summer.
OT: Send your syllabus and modules and I'll be happy to give you feedback. Of course, if you show me yours, I'll have to show you mine. LOL
I don't know whether to look at the lack of volume as a good thing or bad... people are sure holding on at this level... I keep reloading on the dips and the gains look good even though I am not selling... hoping to see that big swing back up to 2.00+
I know its not that realistic in the short term, but I can dream can't I?
OT.. Doc. since you're in the mode.. can you check my course shells for the coming term, lol, or at least respond to some of the introductions...?
Nothing like waiting a full week for the next trade only to see that some poor bloke needed $66 (less commission for weekend beer money ).
Very interesting action here this week. People are being forced to buy at ask and there would appear to be very few shares available at that price. Looks like we are 8 weeks away from finding out if SSUR will repeat with back to back profitable quarters.
Still working on it. Gotta love the volume this week.
Doc - we need a source of info here like we have (thanks to you) over on NNVC! Any chances (hint, hint)?
Looks to me like the market is looking for confirmation of the turn around for SSUR from loss to profitable. Back to back positive earnings per share will do amazing things for the share price. Still, the SP right now should be at least 5 times projected annual earnings which would put the minimum price at .40. That's more than double today's closing price. The fact that shares are very hard to come by demonstrates just how strong of a hold current shareholders have on the float. Even recent buying at .25 didn't generate very much volume. Seems to me the price at least needs to get to .60 in order to really stimulate volume and trigger the lowest priced warrants to be exercised (probably closer to .80 in reality).
Moreover, now that Leo is back fully focused on SSUR financials the bottom line should expand. I would not be at all surprised to see Q2 earnings above 2 cents a share.
I really think we might be at the beginning of an uptrend here... chart really looks that way.
Up again and moving slowly but surely toward .30 against a nearly all red market. Only a few bright spots these last 2 days, QLGC, APPL and SSUR. I think this may be the start of a long-term reversal. Then again, maybe not. Any chartists?
From 10K - ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
~22million
So I make the float ~15million.
Authorized 50 million.
What's the float? Buy it up and this will pop to $1+.
PS:
Board box
Share Structure
O/S: 37,379,314 shares as of April 30,2007 per 10Q
Float??
Looks like the bid base has come up two ticks. And, not many shares are available. Looking for .50 in the short-term. A little good news and we should get a nice pop to .30 level. A little more buying and we may get that anyway.
Nor have I. Just placed a test order and it went through.
In the interview with Wallstreet.net the Chairman referred to some potential small tranche fund raising for new products down line, but not at these prices.
Yeah, I called it in with my broker.. and he placed it for me... thats my bid at 0.17 right now.. it only filled 5000
I haven't had trouble.
I still can't place a trade online... anyone else trying to buy?
OK - let me do the math - (3x4)X10=$1.20, it's now ~20¢=a 6 bagger.
And the best feature is that the guy in charge has a $Billion achievement in his past corporate building accomplishments.
It won't be 20¢ for long!
I agree. certainly not less than 5 times, even if the market is waiting for a second quarter to confirm the turn around. Here's the deal though. They not only had a 2 cent profit, but they also paid down more than $1 million of the long-term debt. If that is the case, and I am interpreting the financials correctly, then throw in that pay down and earnings were actually 3 cents.
I thought it was for the year - the quarter means it deserves 10X (in my book) which makes it worth 80¢!
back to .17 time to load up some more..
Price to earnings is annual. .02 for the Q equals .08 for the year. 20 cents is 2.5 times eps. When I posted 2X earnings .17 had just gone off.
Doc, re--the current price at 2 times earnings--??
It's 10X at 20¢, is it not?
Let me get this right. The 10Q showed a reversal of fortune for the company and a .02 profit and the bounce poops out because:
It's Monday.
Beginning of summer.
MMs created a 20% spread.
I completed filling my position Friday.
Choose any combo of the above.
With the current price at 2 times earnings, maybe people are looking for 2 profitable quarters in a row? Surely, the SP should be at least 5 times earnings right now.
westeffer,
Just listened to the interview and also checked out the patents and the website etc. etc.
Very impressive.
TIA
Brent
I have indeed! IMA is a world class outfit and Chembio is the manufacturer with a record of achievement and all the proper established validated facilities. As Steve said, SSUR is an R&D type outfit - the invention and patent side - they outsource the manufacture and marketing. I'm waiting for and expecting an avian flu barrel based tester to either be developed or introduced ASAP. Perhaps even with NNVC's help and assistance (Seymour IS the common denominator between SSUR and NNVC).
Look at the two companyies they are in partnership with.... IMA has a market cap of 2.2 billion.
I have now, thanks to you. And I read this PR, too:
May 31, 2007 - 6:30 AM EDT
StatSure Diagnostic Systems CEO Featured in Exclusive Interview With WallSt.net
NEW YORK, May 31 /PRNewswire-FirstCall/ -- On May 23, Steve Peltzman, CEO for StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR) updated the investment community in an exclusive interview with www.wallst.net. Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, current capitalization, upcoming strategic and financial milestones.
To hear the interview in its entirety, visit www.wallst.net, and click on 'Interviews.' The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the 'Interviews' section of the site, or by entering the company's ticker symbol in the Search Archive window.
About StatSure Diagnostic Systems:
StatSure Diagnostic Systems, Inc. is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral-fluid collection devices. The Company's proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of the company's diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. Certain of these products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations.
For more information about the company, please visit http://www.statsure.com .
About WallSt.net:
www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The website is a leading provider of financial news, media, tools and community-driven applications for investors. www.wallst.net offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications. In addition to its website, WallStreet Direct organizes investor conferences, publishes a newspaper, and provides multimedia advertising solutions to small and mid-sized publicly traded companies. We are expecting to receive two hundred eighty dollars from StatSure Diagnostic Systems, Inc. for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO )
SOURCE WallStreet Direct, Inc.
Source: PR Newswire (May 31, 2007 - 6:30 AM EDT)
http://app.quotemedia.com/quotetools/popups/story.jsp
Looks good - I particularly liked the 'avian flu' and 'P&G' mentions. With P&G involved with an avian flu home use test device - I see mega sales. I think we are looking at an NNVC clone - albeit in a somewhat different but related field.
scoturd made me call to put an order in... no internet buys allowed now.. they said it was due to the high % run up today... glad I got in last week @ .15... thanks Nano.. ;)
Did you listen to the CEO interview today on Wallstreet.net? Pretty interesting future in a huge field/superior product and now in a 3 way partnership for the future. Worth listening to. I had a very tough time picking up shares today.
New device detects avian flu strains fast
(Reuters) 30 May 2007
WASHINGTON - A new device can quickly detect 92 different viruses, including several strains of the feared H5N1 avian flu virus or other emerging new infections, US researchers reported on Tuesday.
They said their mass spectrometer device could also be used in big hospitals to watch for outbreaks of dangerous drug-resistant infections.
“Therefore, we can keep up with the virus, even if there is a new variant of H5N1 circulating that is different from last year’s,” Ranga Sampath, executive director of Ibis Biosciences Inc., told Reuters.
Carlsbad, Californina-based Ibis, a division of Isis Pharmaceuticals, ISIS.O, worked with US military researchers to fine-tune their device and test it against a range of flu viruses.
Flu is difficult to monitor because spot tests cannot identify the precise strain. When testing people for the H5N1 flu virus, the World Health Organization uses specialized labs that can spend weeks first growing and then testing tiny samples of virus.
The new detector, called the T5000, works in just four hours to identify the precise strain, the company reported in the Public Library of Science.
Ibis researchers worked with teams at the Naval Medical Research Unit in Cairo, Egypt, US Army Medical Research in Infectious Diseases at Ft. Detrick, Maryland, Johns Hopkins University in Baltimore and other groups to test the T5000.
“We detected and correctly identified 92 mammalian and avian influenza isolates, representing 30 different H and N types, including 29 avian H5N1 isolates,” the company said.
The device was 97 percent accurate in identifying the flu strain infecting 656 people who gave specimens between 1999 and 2006, it said.
WHO and the US Centers for Disease Control and Prevention have been calling with greater and greater urgency for new and better diagnostic tests for flu and other microbes.
Watching for a pandemic
H5N1 is especially feared now because it has killed 186 people out of 307 infected. Although it only rarely infects humans, it could mutate into a form that transmits easily from one person to another.
That would cause a pandemic that could kill millions in a few months, or something else could. Experts would like quick tests so they know what is infecting people who become suddenly or mysteriously ill.
“Everybody’s worried about H5N1. It might be H5N1, or it could be any other avian flu off the charts of everybody’s radar at the moment,” Ibis’s Dave Ecker said in a telephone interview.
“Molecular tests are like launching a ship. You just can’t keep up with either the breadth of infectious agents or the way they mutate and change over time,” Ecker added. “We design the test for whole groups of microbes or all families of microbes.”
The T5000 first uses a process called polymerase chain reaction or PCR to amplify the genetic material in a sample of virus or bacteria so it can be tested. It then uses an advanced mass spectrometry technique to identify the sample.
Ecker said the device is not portable and is not cheap.
It is about 6 feet long and three feet tall (two metres long and a metre tall) . It costs between $400,000 and $500,000, so only large institutions or governments could invest in one.
But Ecker said using the device to screen for outbreaks of drug-resistant bacteria could save a big hospital close to that much in a year, because such infections are difficult to control and very expensive to treat.
http://www.khaleejtimes.com/DisplayArticleNew.asp?xfile=data/theworld/2007/May/theworld_May846.xml&a....
Room for improvement in size, speed and cost!!
Chembio's video of the HIV Barrel test product use:
SURE CHECK® HIV 1/ 2 Assay Procedural Video
http://www.chembiodiagnostics.com/humantest4.html
(At bottom of page)
Thanks Nano.
He just resigned as CFO at NNVC:
http://biz.yahoo.com/e/070523/nnvc.pk8-k.html
Marked
I see that Leo Ehrlich, SSUR Chief Financial Officer, is also a member of the Board of Directors at NNVC.
US patent 5,935,864 - Method and kit for collecting samples of liquid specimens for analytical testing
http://v3.espacenet.com/origdoc?DB=EPODOC&IDX=US5935864&F=0&QPN=US5935864
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fne...
Saliva Diagnostic Systems, Inc. and StatSure Diagnostic Systems - SSUR
From
http://sec.edgar-online.com/2007/03/08/0001144204-07-011794/Section3.asp
At the beginning of business on January 24, 2006, the Company effected a name
change from Saliva Diagnostic Systems, Inc. to StatSure Diagnostic Systems,
Inc., and the shares of the Company have been trading under that name, with the
new symbol SSUR, since March 22, 2006. Coinciding with our corporate name
change, the Company has changed the brand of its Hema-Strip Product line, in
general, to StatSure(TM), and the name of its Hema-Strip HIV test to
StatSure(TM) HIV.
StatSure(TM) Diagnostic Systems, Inc., (SDS), a Delaware corporation (the
"Company"), is primarily engaged in the development and marketing of oral fluid
collection devices for the drugs of abuse market, and rapid, point-of-care
immunoassays for use in the detection of infectious diseases. The Company
believes that its patented, proprietary platform offers significant advantages
over the existing products, including ease-of-use, lower costs, and
significantly reduced risk of infection from collecting and handling specimens.
In the oral fluid collection market, the Company's platform has a patented
internal quality control that indicates sufficient volume of the oral fluid
("volume adequacy indicator").
The Company was incorporated in California in 1986 as E&J Systems, Inc. In
January 1992, the Company merged into a Delaware corporation and, at that time,
changed its name to Saliva Diagnostic Systems, Inc. The Company completed an
initial public offering of its common stock in March 1993. In January, 2006, the
Company changed its name to StatSure Diagnostic Systems, Inc. The Company's
principal executive offices are located at 1Clarks Hill Rd. Framingham, MA.
01702.
In May 2002, the Company received its Investigational Device Exemption (IDE)
from the U.S. Food and Drug Administration (FDA) for its Rapid Stat-Sure(TM) HIV
Test [THE PRODUCT BRAND NAME WAS FORMERLY KNOWN AS HEMA-STRIP HIV; THIS PRODUCT LINE WILL HEREAFTER BE REFERRED TO AS THE STATSURE PRODUCT LINE AND THIS PRODUCT WILL BE KNOWN AS STATSURE HIV]. Upon termination of all business relationships with its then contract manufacturer, Chembio Diagnostic Systems, (CEMI.OB) the
Company signed a Manufacturing / Research & Development Agreement with American
Bio Medica Corporation, Nasdaq SC (ABMC), of Kinderhook, NY. Responsibilities of
ABMC include the manufacture of the Company's StatSure(TM) HIV test and other
products under appropriate and applicable regulatory compliance standards. The
Company filed a new IDE with the FDA naming ABMC as its contract manufacturer.
This IDE submission to the FDA was made in October 2003. Thereafter, the Company
conducted its clinical trials and submitted all the modules of the Pre-Market
Approval (PMA) to the FDA. The FDA requested certain additional testing and the
Company completed this work in the summer of 2005 and a Supplemental Study to
the PMA was submitted in October 2005 to satisfy this request. The Company is
currently waiting for the FDA to complete its audits of certain clinical sites
and of the Company's contract manufacturer. Should the Company receive PMA
approval for its rapid HIV test, it will also file for a CLIA (Clinical
Laboratory Improvements Amendments) waiver. During the past year, the Company
has received regulatory approval to markets its StatSure(TM) HIV product in
South Africa and Guatemala and expects to receive similar approvals in several
other countries in 2006. (See also Item 6- Management's Discussion And Analysis
of Financial Condition And Results of Operations; Subsequent Events)
SDS is committed to and focused on the completion of the necessary requirements
towards obtaining U.S. Food and Drug Administration (FDA) PMA marketing approval
of our rapid Stat-Sure(TM) HIV diagnostic tests in the United States. Although
there is no assurance that we will receive approval, we believe that the
StatSure(TM) HIV device format, if approved for detecting antibodies to HIV-1 in
fingerstick and venipuncture whole blood, serum and plasma samples, will have
certain competitive advantages in the market for rapid HIV testing both in the
United States and internationally.
Ref:
STATSURE DIAGNOSTIC (OTC BB:SSUR.OB)
http://finance.yahoo.com/q?s=SSUR.OB
NB:
Our business model calls for rapidly expanding our business. We feel the Inverness/Chembio agreement, validated our barrel patent and the commercial potential of the technology platform. There is a broad menu of potential products that we are candidates for development using the barrel assay format. They include hepatitis B and C, SARS, bird-flu, and others. The Company is currently seeking funds to use to target the development of one or more of these product opportunities. While we are very excited about the potential of the base HIV business, we also want to leverage our technology platform to broaden this product base.
http://www.statsurediagnostics.com/index.php?press
(Kinda reminds me of NNVC at 10¢ - time for ANOTHER flier??!! Bid: 0.14 x 5000 Ask: 0.20 x 5000)
US Patent 5,935,864 - StatSure Hemastrip:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fne....
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
145
|
Created
|
05/27/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |